Skip to content

Regulatory Considerations Expert Group reviews draft FDA Guidance

Date: June 19, 2023

The ACDM Regulatory Considerations Expert Group have reviewed and submitted comments on the recent draft FDA Guidance: Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations Questions and Answers.

The guidance provides an overall overview about the most relevant key points to consider on the use of electronic systems, electronic records and electronic signatures in clinical investigations. It also provides recommendations regarding the requirements, under 21 CFR part 11, under which FDA considers electronic systems, electronic records, and electronic signatures to be trustworthy, reliable, and generally equivalent to paper records and handwritten signatures executed on paper.

This guidance has been open for public consultation and the Regulatory Considerations Expert Group have provided feedback to the FDA on some points that may need further clarity, on behalf of the ACDM. The final guidance is expected to be released once the FDA have reviewed and agreed on implementation feedback received for the whole international clinical trials community.

The ACDM Regulatory Considerations Expert Group looks at providing guidance information on a number of areas surrounding regulations. If you are interested in joining, find out more here: https://acdmglobal.org/regulatory-considerations-dmeg/

 


 

Explore More News

Welcome Climedo as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome Climedo as a . . .

Read More

Clinical Trials for Medicines – New Notification Scheme

The MHRA have recently launched a new notification scheme, the first step in their . . .

Read More

EMA Management Board: Highlights of October 2023 meeting

The EMA’s Management Board met on 5 October in Amsterdam. The article below covers the . . .

Read More

Welcome Mednet as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome Mednet as a new . . .

Read More

Welcome Allucent as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome Allucent as a . . .

Read More

Welcome KCR as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome KCR as a new . . .

Read More

Welcome Debiopharm as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome Debiopharm as a . . .

Read More

HMA/EMA joint Big Data Steering Group: Big Data Workplan 2023-2025

The joint HMA-EMA Big Data Steering Group (BDSG) have released their latest workplan, . . .

Read More

ACT EU PA04 – Multi-stakeholder Workshop on ICH E6 R3

As part of the Accelerating Clinical Trials in the EU (ACT EU) multi-annual workplan . . .

Read More

European Medicine’s Agency – Reflection paper on the use of artificial intelligence in the lifecycle of medicines

The EMA has opened a public consultation on a reflection paper presenting views . . .

Read More

Welcome Instem as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome Instem as a new . . .

Read More

Regulatory Considerations Expert Group reviews draft FDA Guidance

The ACDM Regulatory Considerations Expert Group have reviewed and submitted comments on . . .

Read More